Stocks Health care ARVN
NASDAQ · Health careArvinas, Inc. (ARVN)
Arvinas, Inc. brought in $275.3M of revenue over the twelve months to September 30, 2026, down 11.8% from a year earlier. It posted a net loss of $9.5M. In fiscal 2025 capital spending exceeded operating cash flow by $275.7M. At September 30, 2026 it held $88M in cash against $400K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Arvinas, Inc.
- Net worth
- Arvinas, Inc. has a market value (market cap) of $439.4M at the latest share price, and shareholders' equity of $513.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $262.6M (-0.3% year on year), with a net loss of $80.8M. Over the 12 months to September 30, 2026: revenue $275.3M, net loss $9.5M.
- Cash flow
- In fiscal 2025 operations used $273.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Arvinas, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Arvinas, Inc. does
Arvinas, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARVN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $262.6M | -$80.8M | -$1.14 | -$275.7M |
| 2024 | $263.4M | -$198.9M | -$2.77 | -$261.1M |
| 2023 | $78.5M | -$367.3M | -$6.62 | -$350.7M |
| 2022 | $131.4M | -$282.5M | -$5.31 | -$280.3M |
| 2021 | $53.6M | -$191M | -$3.82 | $554.7M |
| 2020 | $25.9M | -$119.3M | -$3.02 | -$96.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ARVN ranks in Health care
Latest SEC filings
What Arvinas, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 99% to $500K versus the same quarter last year; diluted EPS -$0.82 versus -$0.48.
- November 3, 2026
- September 28, 2026
- August 31, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1,015% to $249.7M versus the same quarter last year; diluted EPS $2.58 versus -$0.84.
- August 4, 2026
- June 25, 2026
- June 22, 2026
Insider trades
What the people running Arvinas, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 9, 2026 | Loomis David KVP, Chief Accounting Officer | Soldpre-planned (10b5-1) | 232 | $1.5K |
| June 24, 2026 | Bain LindaDirector | Received as pay | 15,527 | - |
| June 24, 2026 | Cunningham EverettDirector | Received as pay | 15,527 | - |
| June 24, 2026 | Kennedy Edward Moore Jr.Director | Received as pay | 15,527 | - |
| June 24, 2026 | Morrison BriggsDirector | Received as pay | 15,527 | - |
| June 24, 2026 | Norwalk Leslie VDirector | Received as pay | 15,527 | - |
| June 24, 2026 | Smaldone Alsup LaurieDirector | Received as pay | 15,527 | - |
| June 24, 2026 | Saik AndrewChief Financial Officer | Soldpre-planned (10b5-1) | 5,696 | $46.5K |
Who owns ARVN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Portfolio Management13G, passive | 6.12% | April 28, 2026 |
| D. E. Shaw & Co., L.P.13G, passive with 2 related filers | 5.4% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 201 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 7,609,123 | +811,539 |
| Vanguard Portfolio Management LLC | 4,123,399 | +233,771 |
| D. E. Shaw & Co., Inc. | 3,495,153 | -143,414 |
| Pfizer Inc | 3,457,815 | 0 |
| Armistice Capital, LLC | 2,796,000 | +818,000 |
| Vanguard Capital Management LLC | 2,714,163 | +24,801 |
| Two Sigma Investments, LP | 2,573,447 | +741,333 |
| State Street Corp | 2,196,872 | +368,400 |
| Nextech Invest Ltd. | 1,122,713 | +583,319 |
| Geode Capital Management, LLC | 1,667,265 | +110,158 |
| Qube Research & Technologies Ltd | 1,592,276 | +390,641 |
| Jacobs Levy Equity Management, Inc | 1,412,643 | -28,878 |
| Federated Hermes, Inc. | 1,356,032 | +215,317 |
| Hillsdale Investment Management Inc. | 750,900 | new |
| TCG Crossover Management, LLC | 707,098 | -1,680,363 |
| Dimensional Fund Advisors LP | 654,909 | +169,145 |
| Goldman Sachs Group Inc | 640,811 | -116,064 |
| Citadel Advisors LLC | 620,973 | -560,015 |
| Northern Trust Corp | 615,296 | +94,341 |
| Aqr Capital Management LLC | 601,873 | +316,755 |
Insiders
12 insiders reported holding 2,339,163 shares in total, about $15.7M at the last price.
| Holder | Shares |
|---|---|
| Houston John GDirector | 1,122,183 |
| Teel RandyPresident and CEO, Director | 285,009 |
| Berkowitz NoahChief Medical Officer | 191,395 |
| Saik AndrewChief Financial Officer | 187,432 |
| Cacace Angela MChief Scientific Officer | 180,390 |
| Morrison BriggsDirector | 111,548 |
| Kennedy Edward Moore Jr.Director | 54,957 |
| Bain LindaDirector | 41,572 |
| Smaldone Alsup LaurieDirector | 41,572 |
| Cunningham EverettDirector | 41,572 |
Questions about ARVN
What does Arvinas, Inc. do?
Arvinas, Inc. is a company in the Health care sector, listed on NASDAQ as ARVN. Its shares trade on NASDAQ under the ticker ARVN.
What is Arvinas, Inc.'s net worth?
Arvinas, Inc. has a market value (market cap) of $439.4M at the latest share price, and shareholders' equity of $513.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Arvinas, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $9.5M on revenue of $275.3M.
How much revenue does Arvinas, Inc. make?
Over the twelve months to September 30, 2026 Arvinas, Inc. reported revenue of $275.3M. That is 11.8% less than a year earlier.
When did Arvinas, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 9, 2026.
When is Arvinas, Inc.'s next earnings report?
Arvinas, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ARVN with
Follow ARVN
Get an email when Arvinas, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Arvinas, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.